Cargando…

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of “toxic warheads”, ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, Ricarda M., Coumbe, Ben G. T., Josephs, Debra H., Mele, Silvia, Ilieva, Kristina M., Cheung, Anthony, Tutt, Andrew N., Spicer, James F., Thurston, David E., Crescioli, Silvia, Karagiannis, Sophia N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769674/ https://www.ncbi.nlm.nih.gov/pubmed/29375935 http://dx.doi.org/10.1080/2162402X.2017.1395127

Ejemplares similares

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
por: Ilieva, Kristina M., et al.
Publicado: (2018)

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
por: Esapa, Benjamina, et al.
Publicado: (2023)

AllergoOncology: Expression platform development and functional profiling of an anti‐HER2 IgE antibody
por: Ilieva, Kristina M., et al.
Publicado: (2019)

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields
por: Ilieva, Kristina M., et al.
Publicado: (2017)

In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model
por: Williams, Iwan P., et al.
Publicado: (2019)

Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells
por: Correa, Isabel, et al.
Publicado: (2018)

In Planta Glycan Engineering and Functional Activities of IgE Antibodies
por: Montero-Morales, Laura, et al.
Publicado: (2019)

BRAF inhibitors: resistance and the promise of combination treatments for melanoma
por: Griffin, Merope, et al.
Publicado: (2017)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
por: Mantaj, Julia, et al.
Publicado: (2016)

Therapeutic targets and new directions for antibodies developed for ovarian cancer
por: Bax, Heather J., et al.
Publicado: (2016)

In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart
por: Man, Francis, et al.
Publicado: (2021)

Site-Specific Antibody Conjugation for ADC and Beyond
por: Zhou, Qun
Publicado: (2017)

IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states
por: Pellizzari, Giulia, et al.
Publicado: (2019)

Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology
por: Crescioli, Silvia, et al.
Publicado: (2018)

Special Issue “Antibody Engineering for Cancer Immunotherapy”
por: Crescioli, Silvia, et al.
Publicado: (2022)

B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
por: Chiaruttini, Giulia, et al.
Publicado: (2017)

Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients
por: Karagiannis, Panagiotis, et al.
Publicado: (2021)

Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)
por: Yao, Houzong, et al.
Publicado: (2016)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Targeting folate receptor alpha for cancer treatment
por: Cheung, Anthony, et al.
Publicado: (2016)

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies
por: Osborn, Gabriel, et al.
Publicado: (2021)

Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies
por: Kang, Xiuhua, et al.
Publicado: (2018)

Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)
por: Mahmood, Iftekhar
Publicado: (2021)

Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance
por: Mahmood, Iftekhar
Publicado: (2021)

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
por: Koster, Kira-Lee, et al.
Publicado: (2022)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

IgE Antibodies against Cancer: Efficacy and Safety
por: Chauhan, Jitesh, et al.
Publicado: (2020)

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation
por: Cini, Elena, et al.
Publicado: (2018)

Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
por: Lambert, John M., et al.
Publicado: (2017)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
por: Willsmore, Zena N., et al.
Publicado: (2021)

Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism
por: Tumey, L. Nathan, et al.
Publicado: (2016)

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs
por: Kumar, Amit, et al.
Publicado: (2018)

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
por: Hammood, Manar, et al.
Publicado: (2021)

Antibodies as biomarkers for cancer risk: a systematic review
por: Monroy-Iglesias, Maria J, et al.
Publicado: (2022)

Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
por: Chauhan, Jitesh, et al.
Publicado: (2023)

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
por: Lucas, Andrew T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nu054f8447jc936icghinlnaq2